U.S. Markets open in 1 hr 2 mins

Merrimack Pharmaceuticals, Inc. (MACK)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.20-0.04 (-3.23%)
At close: 4:00PM EDT
People also watch
FOLDACHNSGYPCLDXARRY

Merrimack Pharmaceuticals, Inc.

One Kendall Square
Suite B7201
Cambridge, MA 02139
United States
617-441-1000
http://www.merrimackpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees294

Key Executives

NameTitlePayExercisedAge
Dr. Ulrik B. Nielsen Ph.D.Co-Founder & Director45k982k45
Dr. Richard Peters M.D., Ph.D.Pres, CEO & DirectorN/AN/A54
Dr. Anthony J. Sinskey Sc.D.Co-Founder and Scientific AdvisorN/AN/A77
Dr. Gavin MacBeath Ph.D.FounderN/AN/AN/A
Mr. John L. GreenPrincipal Accounting Officer & ControllerN/AN/A37
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. Its therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Merrimack Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.